Roche Considers Divesting $1.9 Billion Cancer Data Startup
Roche is evaluating options for its $1.9 billion investment in Flatiron Health, potentially including divestment.
- Latest
- Trending
Roche is evaluating options for its $1.9 billion investment in Flatiron Health, potentially including divestment.
DaVita increases 2024 profit outlook due to high demand for kidney dialysis services, boosting shares by 3% in aftermarket trade.
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Interlynk to provide SBOM generation, vulnerability reporting, and risk assessment for BIOTRONIK's life-saving products.
Amgen's Q2 profit drops due to higher expenses, but revenue sees a 20% increase, driven by Horizon acquisition.
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
22nd Century Group cuts debt by $1.5M, aiming for financial stability and progress in tobacco harm reduction using advanced technology.
"AI in Medical Diagnostics set to skyrocket to USD 30.76 billion by 2032, driven by rapid advancements and major industry ...
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.